Idiopathic pulmonary fibrosis (IPF) research hub
10 indexed studies · 7 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis
This study is testing a new medicine called zampilimab for idiopathic pulmonary fibrosis (IPF). It aims to see if two different doses of zampilimab are safe and work better than a dummy medicine over 24 weeks, with an optional longer period.
Belgium · Germany · Italy - recruitingPHASE2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
This study is looking into a new drug, AZD8965, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if different doses of this drug are safe and effective, compared to a dummy drug, for people with IPF, including those already on other treatments.
United States · Argentina · Australia - completed
What is the best treatment and the most cost effective treatment for patients with idiopathic pulmonary fibrosis (IPF): advice on breathlessness, or advice on breathlessness and oxygen to use whilst walking and doing other daily activities at home?
The OXYPuF trial looks at the best way to help people with idiopathic pulmonary fibrosis (IPF) who get out of breath. It compares standard advice on managing breathlessness against advice combined with portable home oxygen tanks used during daily activities. The aim is to see which improves quality of life most.
United Kingdom · England - recruitingPhase II and Phase III (Integrated)
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
This study is looking at a new medicine called bexotegrast for idiopathic pulmonary fibrosis (IPF). It aims to see if the medicine can help improve lung function and slow down the disease, and if it's safe to use. Some participants will receive the medicine, and others a dummy pill.
Greece · France · Netherlands - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
This study is testing a new tablet, called NAL ER, to see if it can help reduce coughing in people with Idiopathic Pulmonary Fibrosis (IPF). Researchers want to find out if it is safe and if different doses work better than a dummy pill (placebo).
Germany · Netherlands · Italy - recruitingPHASE2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
This study is testing a new inhaled medicine, LTI-03, for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if LTI-03 is safe, helps with lung scarring, and improves IPF symptoms.
United States · Australia · Bulgaria - recruitingPHASE2
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
This study is testing a new way to give nintedanib medicine for lung scarring (IPF). It sees if a breathed-in solution (AP02) can improve lung function and is safe. Some people will get the medicine, others a dummy treatment.
Australia · Canada · Germany - recruitingPHASE2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
This study is for people who were in a previous study with an inhaled medicine called AP01 for lung scarring (pulmonary fibrosis). It’s an extension to see how the medicine works over a longer time, using an inhaler twice a day.
United States · Argentina · Australia - active not recruitingPHASE2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
This study, called ASPIRE, is testing a new medication, Buloxibutid, for Idiopathic Pulmonary Fibrosis (IPF). It compares the new drug to a dummy pill (placebo) to see if it's safe and helps improve lung function over 52 weeks.
United States · Argentina · Australia - recruiting
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
This study looks at how anti-fibrotic medicines for lung scarring might affect your body shape, specifically your muscle and fat. It uses simple tests like body scanners and muscle scans to see if these medicines cause changes not picked up by just weighing yourself.
United Kingdom